1
|
Furnari FB, Fenton T, Bachoo RM, Mukasa A,
Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al:
Malignant astrocytic glioma: Genetics, biology, and paths to
treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
|
2
|
Sayegh ET, Kaur G, Bloch O and Parsa AT:
Systematic review of protein biomarkers of invasive behavior in
glioblastoma. Mol Neurobiol. 49:1212–1244. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Kim GW, Lee DH, Yeon SK, Jeon YH, Yoo J,
Lee SW and Kwon SH: Temozolomide-resistant glioblastoma depends on
HDAC6 activity through regulation of DNA mismatch repair.
Anticancer Res. 39:6731–6741. 2019. View Article : Google Scholar : PubMed/NCBI
|
5
|
Linz U: Commentary on effects of
radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet
Oncol. 2009; 10: 459–466). 2009; 10: 459–466). Cancer.
116:1844–1846. 2010. View Article : Google Scholar : PubMed/NCBI
|
6
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C,
Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Lai EC: Micro RNAs are complementary to
3′UTR sequence motifs that mediate negative post-transcriptional
regulation. Nat Genet. 30:363–364. 2002. View Article : Google Scholar : PubMed/NCBI
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Adams BD, Kasinski A and Slack FJ:
Aberrant regulation and function of microRNAs in cancer. Curr Biol.
24:R762–R776. 2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Cowland JB, Hother C and Grønbaek K:
MicroRNAs and cancer. APMIS. 115:1090–1106. 2007. View Article : Google Scholar : PubMed/NCBI
|
11
|
Chen H, Liu T, Liu J, Feng Y, Wang B, Wang
J, Bai J, Zhao W, Shen Y, Wang X, et al: Circ-ANAPC7 is upregulated
in acute myeloid leukemia and appears to target the MiR-181 family.
Cell Physiol Biochem. 47:1998–2007. 2018. View Article : Google Scholar : PubMed/NCBI
|
12
|
Xia S, Tian H, Fan L and Zheng J:
Peripheral blood miR-181-5p serves as a marker for screening
patients with osteoarthritis by targeting TNFα. Clin Lab.
63:1819–1825. 2017. View Article : Google Scholar : PubMed/NCBI
|
13
|
Zhu W, Shan X, Wang T, Shu Y and Liu P:
miR-181b modulates multidrug resistance by targeting BCL2 in human
cancer cell lines. Int J Cancer. 127:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
|
14
|
Guo X, Zhu Y and Hong X, Zhang M, Qiu X,
Wang Z, Qi Z and Hong X: miR-181d and c-myc-mediated inhibition of
CRY2 and FBXL3 reprograms metabolism in colorectal cancer. Cell
Death Dis. 8:e29582017. View Article : Google Scholar : PubMed/NCBI
|
15
|
Wang XF, Shi ZM, Wang XR, Cao L, Wang YY,
Zhang JX, Yin Y, Luo H, Kang CS, Liu N, et al: MiR-181d acts as a
tumor suppressor in glioma by targeting K-ras and Bcl-2. J Cancer
Res Clin Oncol. 138:573–584. 2012. View Article : Google Scholar : PubMed/NCBI
|
16
|
Zhang W, Zhang J, Hoadley K, Kushwaha D,
Ramakrishnan V, Li S, Kang C, You Y, Jiang C, Song SW, et al:
miR-181d: A predictive glioblastoma biomarker that downregulates
MGMT expression. Neuro Oncol. 14:712–719. 2012. View Article : Google Scholar : PubMed/NCBI
|
17
|
Chen YY, Ho HL, Lin SC, Ho TDH and Hsu CY:
Upregulation of miR-125b, miR-181d, and miR-221 predicts poor
prognosis in MGMT promoter-unmethylated glioblastoma patients. Am J
Clin Pathol. 149:412–417. 2018. View Article : Google Scholar : PubMed/NCBI
|
18
|
Allard JB and Duan C: IGF-binding
proteins: Why do they exist and why are there so many? Front
Endocrinol (Lausanne). 9:1172018. View Article : Google Scholar : PubMed/NCBI
|
19
|
Duan C, Ren H and Gao S: Insulin-like
growth factors (IGFs), IGF receptors, and IGF-binding proteins:
Roles in skeletal muscle growth and differentiation. Gen Comp
Endocrinol. 167:344–351. 2010. View Article : Google Scholar : PubMed/NCBI
|
20
|
Nielsen EM, Hansen L, Lajer M, Andersen
KL, Echwald SM, Urhammer SA, Hansen T and Pedersen O: A common
polymorphism in the promoter of the IGF-I gene associates with
increased fasting serum triglyceride levels in glucose-tolerant
subjects. Clin Biochem. 37:660–665. 2004. View Article : Google Scholar : PubMed/NCBI
|
21
|
Li Z, Pan W, Shen Y, Chen Z, Zhang L,
Zhang Y, Luo Q and Ying X: IGF1/IGF1R and microRNA let-7e
down-regulate each other and modulate proliferation and migration
of colorectal cancer cells. Cell Cycle. 17:1212–1219. 2018.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Wang H, Tang C, Na M, Ma W, Jiang Z, Gu Y,
Ma G, Ge H, Shen H and Lin Z: miR-422a inhibits glioma
proliferation and invasion by targeting IGF1 and IGF1R. Oncol Res.
25:187–194. 2017. View Article : Google Scholar : PubMed/NCBI
|
23
|
LoRusso PM: Inhibition of the
PI3K/AKT/mTOR pathway in solid tumors. J Clin Oncol. 34:3803–3815.
2016. View Article : Google Scholar : PubMed/NCBI
|
24
|
Chen B, Xue Z, Yang G, Shi B, Yang B, Yan
Y, Wang X, Han D, Huang Y and Dong W: Akt-signal integration is
involved in the differentiation of embryonal carcinoma cells. PLoS
One. 8:e648772013. View Article : Google Scholar : PubMed/NCBI
|
25
|
Saiki S, Sasazawa Y, Imamichi Y, Kawajiri
S, Fujimaki T, Tanida I, Kobayashi H, Sato F, Sato S, Ishikawa KI,
et al: Caffeine induces apoptosis by enhancement of autophagy via
PI3K/Akt/mTOR/p70S6K inhibition. Autophagy. 7:176–187. 2011.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Liu G, Zhao X, Zhou J, Cheng X, Ye Z and
Ji Z: LncRNA TP73-AS1 promotes cell proliferation and inhibits cell
apoptosis in clear cell renal cell carcinoma through repressing
KISS1 expression and inactivation of PI3K/Akt/mTOR signaling
pathway. Cell Physiol Biochem. 48:371–384. 2018. View Article : Google Scholar : PubMed/NCBI
|
27
|
Ye R, Dai N, He Q, Guo P, Xiang Y and
Zhang Q, Hong Z and Zhang Q: Comprehensive anti-tumor effect of
Brusatol through inhibition of cell viability and promotion of
apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in
hepatocellular carcinoma. Biomed Pharmacother. 105:962–973. 2018.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Dai Z, Wang L, Wang X, Zhao B, Zhao W,
Bhardwaj SS, Ye J, Yin Z, Zhang J and Zhao S: Oxymatrine induces
cell cycle arrest and apoptosis and suppresses the invasion of
human glioblastoma cells through the EGFR/PI3K/Akt/mTOR signaling
pathway and STAT3. Oncol Rep. 40:867–876. 2018.PubMed/NCBI
|
29
|
National Research Council (US) Committee
on Recognition and Alleviation of Pain in Laboratory Animals, .
Recognition and alleviation of pain in laboratory animals.
Washington (DC): National Academies Press (US); 2009
|
30
|
Su XW, Lu G, Leung CK, Liu Q, Li Y, Tsang
KS, Zhao SD, Chan DTM, Kung HF and Poon WS: miR-181d regulates
human dendritic cell maturation through NF-κB pathway. Cell Prolif.
50:e123582017. View Article : Google Scholar
|
31
|
Ho KH, Chen PH, His E, Shih CM, Chang WC,
Cheng CH, Lin CW and Chen KC: Identification of IGF-1-enhanced
cytokine expressions targeted by miR-181d in glioblastomas via an
integrative miRNA/mRNA regulatory network analysis. Sci Rep.
7:7322017. View Article : Google Scholar : PubMed/NCBI
|
32
|
Chen J, Zeng J, Xin M, Huang W and Chen X:
Formononetin induces cell cycle arrest of human breast cancer cells
via IGF1/PI3K/Akt pathways in vitro and in vivo. Horm Metab Res.
43:681–686. 2011. View Article : Google Scholar : PubMed/NCBI
|
33
|
Zhang L, He X, Li F, Pan H, Huang X, Wen
X, Zhang H, Li B, Ge S, Xu X, et al: The miR-181 family promotes
cell cycle by targeting CTDSPL, a phosphatase-like tumor suppressor
in uveal melanoma. J Exp Clin Cancer Res. 37:152018. View Article : Google Scholar : PubMed/NCBI
|